Cullinan Therapeutics, Inc. key statistics and ratios
In fiscal 2022, Cullinan Therapeutics, Inc. had return on equity of 23.2%, debt equal to 0.0% of equity and a current ratio of 21.09. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 |
|---|---|---|---|
| Operating margin | — | −358.7% | — |
| Net margin | — | −346.1% | — |
| Free-cash-flow margin | — | −229.3% | — |
| Return on equity | −26.0% | −21.0% | 23.2% |
| Return on assets | −24.1% | −20.1% | 22.3% |
| Asset turnover | — | 0.06 | — |
| Current ratio | 14.82 | 25.25 | 21.09 |
| Debt to equity | 0.0% | 0.0% | 0.0% |
| Effective tax rate | — | — | 27.8% |
| R&D as % of revenue | — | 304.9% | — |
| Capital spending as % of revenue | — | 0.0% | — |
| Free cash flow ÷ net income | — | — | −114.9% |
| Quarter | 2021 Q1Mar 2021 | 2021 Q2Jun 2021 | 2021 Q3Sept 2021 | 2021 Q4Dec 2021 | 2022 Q1Mar 2022 | 2022 Q2Jun 2022 | 2022 Q3Sept 2022 | 2022 Q4Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 7.2% | — | — | — | — | — | — | — |
| Net margin | −0.4% | — | — | — | — | — | — | — |
| Current ratio | 45.21 | 59.98 | 41.82 | 25.25 | 18.68 | 10.04 | 21.47 | 21.09 |
| R&D as % of revenue | 65.5% | — | — | — | — | — | — | — |
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
More: Biotechnology stocks compared, Health Care sector, rankings of US companies